

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

宜明昂科生物醫藥技術（上海）股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1541)

AMENDMENTS TO THE ARTICLES OF ASSOCIATION

This announcement is made pursuant to Rule 13.51(1) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

Reference is made to the announcements of ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (the “**Company**”) dated November 21 and November 28, 2024 and October 9 and October 16, 2025 (the “**Announcements**”) in relation to the placing of new H shares of the Company (the “**H Shares**”) under the general mandate (the “**Placing**”) and its completion. Upon completion of the Placing, the total number of issued shares of the Company (the “**Shares**”) increased from 407,307,695 Shares to 431,507,695 Shares and the total number of issued H Shares increased from 396,277,305 H Shares to 420,477,305 H Shares. To reflect such changes in the registered capital of the Company, corresponding amendments (the “**Amendments**”) were made to the articles of association of the Company (the “**Articles of Association**”), as detailed below.

Articles No.	Before Amendments	After Amendments
Article 6	The registered capital of the Company is RMB407,307,695.	The registered capital of the Company is RMB407,307,695 RMB431,507,695.
Article 21	The total number of the Company's shares is 407,307,695. All of the Company's shares are ordinary shares.	The total number of the Company's shares is 407,307,695 431,507,695. All of the Company's shares are ordinary shares.

In accordance with the special resolution of the shareholders passed at the annual general meeting of the Company held on May 28, 2025, the board of directors of the Company (the “**Board**”) is authorised to amend, as it may deem appropriate and necessary, relevant articles of the Articles of Association to reflect the change in the share capital structure of the Company in the event of an exercise of the powers granted by such special resolution to allot and issue new Shares.

The full text of the amended Articles of Association is available on the Company’s website at www.immuneonco.com and the Stock Exchange’s website at <http://www.hkexnews.hk>.

Shareholders should be aware that the amended Articles of Association are written in Chinese. In the event of discrepancies between the Chinese version and the English translation of the amended Articles of Association, the Chinese version shall prevail.

By order of the Board
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
宜明昂科生物醫藥技術（上海）股份有限公司
Tian Wenzhi
Chairman and Executive Director

Shanghai, the PRC, November 17, 2025

As at the date of this announcement, the Board of Directors comprises (i) Dr. Tian Wenzhi, Mr. Li Song Ms. Guan Mei and Mr. Zhang Ruliang as executive Directors; (ii) Dr. Xu Cong and Ms. Fu Dawei as non-executive Directors; and (iii) Dr. Zhenping Zhu, Dr. Kendall Arthur Smith and Mr. Yeung Chi Tat as independent non-executive Directors.